Your browser doesn't support javascript.
loading
Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke.
Yu, Di; Liang, Nuanyi; Zebarth, Julia; Shen, Qing; Ozzoude, Miracle; Goubran, Maged; Rabin, Jennifer S; Ramirez, Joel; Scott, Christopher J M; Gao, Fuqiang; Bartha, Robert; Symons, Sean; Haddad, Seyyed Mohammad Hassan; Berezuk, Courtney; Tan, Brian; Kwan, Donna; Hegele, Robert A; Dilliott, Allison A; Nanayakkara, Nuwan D; Binns, Malcolm A; Beaton, Derek; Arnott, Stephen R; Lawrence-Dewar, Jane M; Hassan, Ayman; Dowlatshahi, Dar; Mandzia, Jennifer; Sahlas, Demetrios; Casaubon, Leanne; Saposnik, Gustavo; Otoki, Yurika; Lanctôt, Krista L; Masellis, Mario; Black, Sandra E; Swartz, Richard H; Taha, Ameer Y; Swardfager, Walter.
Affiliation
  • Yu D; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Liang N; Department of Pharmacology and Toxicology University of Toronto Toronto Canada.
  • Zebarth J; Department of Food Science and Technology University of California Davis CA.
  • Shen Q; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Ozzoude M; Department of Pharmacology and Toxicology University of Toronto Toronto Canada.
  • Goubran M; Department of Food Science and Technology University of California Davis CA.
  • Rabin JS; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Ramirez J; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Scott CJM; Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre Toronto Canada.
  • Gao F; Department of Medical Biophysics University of Toronto Toronto Canada.
  • Bartha R; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Symons S; Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre Toronto Canada.
  • Haddad SMH; Division of Neurology, Department of Medicine Sunnybrook Health Sciences Centre Toronto Canada.
  • Berezuk C; Rehabilitation Sciences Institute University of Toronto Toronto Canada.
  • Tan B; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Kwan D; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Hegele RA; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Dilliott AA; Department of Medical Biophysics Western University London Canada.
  • Nanayakkara ND; Center for Functional and Metabolic Mapping, Robarts Research Institute Western University London Canada.
  • Binns MA; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Beaton D; Center for Functional and Metabolic Mapping, Robarts Research Institute Western University London Canada.
  • Arnott SR; Dr. Sandra Black Center for Brain Resilience & Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute Toronto Canada.
  • Lawrence-Dewar JM; Rotman Research Institute, Baycrest Health Sciences Centre Toronto Canada.
  • Hassan A; Centre for Neuroscience Studies Queen's University Kingston Canada.
  • Dowlatshahi D; Robarts Research Institute Western University London Canada.
  • Mandzia J; Department of Neurology and Neurosurgery McGill University Montreal Canada.
  • Sahlas D; Robarts Research Institute Western University London Canada.
  • Casaubon L; Rotman Research Institute, Baycrest Health Sciences Centre Toronto Canada.
  • Saposnik G; Dalla Lana School of Public Health University of Toronto Toronto Canada.
  • Otoki Y; Rotman Research Institute, Baycrest Health Sciences Centre Toronto Canada.
  • Lanctôt KL; Rotman Research Institute, Baycrest Health Sciences Centre Toronto Canada.
  • Masellis M; Thunder Bay Regional Health Research Institute Northern Ontario School of Medicine University Thunder Bay Canada.
  • Black SE; Thunder Bay Regional Health Research Institute Northern Ontario School of Medicine University Thunder Bay Canada.
  • Swartz RH; Department of Medicine (Neurology), Ottawa Hospital Research Institute University of Ottawa Ottawa Canada.
  • Taha AY; Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry Western University London Canada.
  • Swardfager W; Division of Neurology, Department of Medicine, Faculty of Health Sciences McMaster University Hamilton Canada.
J Am Heart Assoc ; 12(1): e026901, 2023 01 03.
Article in En | MEDLINE | ID: mdl-36583428
ABSTRACT
Background Cerebral small vessel disease is associated with higher ratios of soluble-epoxide hydrolase derived linoleic acid diols (12,13-dihydroxyoctadecenoic acid [DiHOME] and 9,10-DiHOME) to their parent epoxides (12(13)-epoxyoctadecenoic acid [EpOME] and 9(10)-EpOME); however, the relationship has not yet been examined in stroke. Methods and Results Participants with mild to moderate small vessel stroke or large vessel stroke were selected based on clinical and imaging criteria. Metabolites were quantified by ultra-high-performance liquid chromatography-mass spectrometry. Volumes of stroke, lacunes, white matter hyperintensities, magnetic resonance imaging visible perivascular spaces, and free water diffusion were quantified from structural and diffusion magnetic resonance imaging (3 Tesla). Adjusted linear regression models were used for analysis. Compared with participants with large vessel stroke (n=30), participants with small vessel stroke (n=50) had a higher 12,13-DiHOME/12(13)-EpOME ratio (ß=0.251, P=0.023). The 12,13-DiHOME/12(13)-EpOME ratio was associated with more lacunes (ß=0.266, P=0.028) but not with large vessel stroke volumes. Ratios of 12,13-DiHOME/12(13)-EpOME and 9,10-DiHOME/9(10)-EpOME were associated with greater volumes of white matter hyperintensities (ß=0.364, P<0.001; ß=0.362, P<0.001) and white matter MRI-visible perivascular spaces (ß=0.302, P=0.011; ß=0.314, P=0.006). In small vessel stroke, the 12,13-DiHOME/12(13)-EpOME ratio was associated with higher white matter free water diffusion (ß=0.439, P=0.016), which was specific to the temporal lobe in exploratory regional analyses. The 9,10-DiHOME/9(10)-EpOME ratio was associated with temporal lobe atrophy (ß=-0.277, P=0.031). Conclusions Linoleic acid markers of cytochrome P450/soluble-epoxide hydrolase activity were associated with small versus large vessel stroke, with small vessel disease markers consistent with blood brain barrier and neurovascular-glial disruption, and temporal lobe atrophy. The findings may indicate a novel modifiable risk factor for small vessel disease and related neurodegeneration.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stroke / Cerebral Small Vessel Diseases Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Am Heart Assoc Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stroke / Cerebral Small Vessel Diseases Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Am Heart Assoc Year: 2023 Document type: Article